SAT0075 Additional target of normal serum matrix metalloproteinase-3 is a potential biomarker for less one-year radiographic progression in rheumatoid arthritis
Authors: L.-F. Chen, J.-D. Ma, Y.-Q. Mo, X.-Y. Du, D.-H. Zheng, L. Dai
Journal: Annals of the Rheumatic Diseases (2018)

<h3>Background</h3> Matrix metalloproteinase (MMP)−3 plays important roles in bone and cartilage destruction in rheumatoid arthritis (RA). Our previous study showed continuously elevated serum MMP-3 for 3–6 months predict one-year radiographic progression in RA (Arthritis Res Ther. 2015 17:289). However, whether serum MMP-3 normalisation is a biomarker for better outcome remains elusive. <h3>Objectives</h3> To explore the association of serum MMP-3 normalisation with clinical and radiographic outcome in RA. <h3>Methods</h3> RA patients with moderate to high disease activity (DAS28-CRP&gt;3.2) were treated according to treat to target (T2T) strategy and followed up at regular intervals (0, 1 st, 3rd, 6th and 12th months). Demographic and clinical data were collected according to the 2017 EULAR recommendation and serum MMP-3 was detected by ELISA at each visit. X-ray assessment of hand/wrist was repeated at baseline and month 12 and radiographic progression was defined as a change of the Sharp/van der Heijde modified sharp score ≥0.5 units. <h3>Results</h3> (<sup>1</sup> Among 200 RA patients recruited, there were 163 (81.5%) female, with median disease duration 24(<sup>11–84</sup> months, median DAS28-CRP 4.9 (4.2–5.7). There were 29% patients showed one-year radiographic progression.<sup>2</sup> The median MMP-3 was 209.7 (108.6–430.0) ng/ml. RA patients without radiographic progression had significant lower level of serum MMP-3 than those with radiographic progression at baseline and each visit (figure 1A, all p&lt;0.001).<sup>3</sup> There were 13.0%, 14.5%, 17.0%, 25.5% and 31.0% patients having normal MMP-3 at baseline and 1 st, 3rd, 6th and 12th months, respectively. There were significantly lower percentage of RA patients with normal MMP-3 at baseline and each visit showed radiographic progression than those with elevated MMP-3 (figure 1B, all p&lt;0.05).<sup>4</sup> There were 8.5%, 13.0%, 20.0% and 25.5% patients who achieved therapeutic target and showed normal MMP-3 at 1 st, 3rd, 6th and 12th months, respectively. Among patients achieved therapeutic target, there were significantly lower percentage of normal MMP-3 patients showed radiographic progression than those with elevated MMP-3 (figure 1C, all p&lt;0.05).<sup>5</sup> There were 6.5%, 11.0%, 14.5%, 20.5% and 25.5% patients who had normal CRP and normal MMP-3 at baseline and 1 st, 3rd, 6th and 12th months, respectively. Among patients with normal CRP, there were significantly lower percentage of normal MMP-3 patients at 1 st, 3rd, 6th and 12th months showed radiographic progression than those with elevated MMP-3 (figure 1D, all p&lt;0.05). <h3>Conclusions</h3> Additional target of normal serum MMP-3 may be a potential biomarker for less one-year radiographic progression. <h3>Acknowledgements</h3> This work was supported by National Natural Science Foundation of China (no. 81471597 and 81671612), Guangdong Natural Science Foundation (no. 2016A030313307 and 2017A030313576) and Guangdong Medical Scientific Research Foundation (no. A2017093 and A2017109). <h3>Disclosure of Interest</h3> None declared